Monitor for actual sales execution in the coming days, as coordinated Form 144 filings from major early investors may signal reduced confidence or capital reallocation. Given the $2.9M scale and recent insider selling trend, consider increased downside risk ahead of potential supply pressure.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 21 $19.21entry
- T+1 · 7mo ago +2.39%α +1.38% · $19.67
- T+5 · 7mo ago −5.47%α −6.55% · $18.16
- T+20 · 6mo ago −13.90%α −18.81% · $16.54
- T+60 · 4mo ago +18.27%α +11.37% · $22.72
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two affiliated venture funds, Atlas Venture Fund XI and Atlas Venture Opportunity Fund I, filed Form 144 notices to sell a combined 198,926 shares of Dyne Therapeutics stock, representing an intent to sell approximately $2.9 million worth of shares. The sales are planned under Rule 144 following private placement acquisitions in 2020.
Key Facts
- Atlas Venture Fund XI filed to sell 142,571 shares, valued at approximately $2.05 million based on recent market price
- Atlas Venture Opportunity Fund I filed to sell 56,355 shares, valued at approximately $815,000
- Total proposed sale: 198,926 shares worth ~$2.87 million
- Shares were acquired in private placements in July and August 2020
- Sales are being conducted through Merrill Lynch in San Francisco
- Both filings were submitted on the same day (April 20, 2026), indicating coordinated action
Financial Impact
$2.87 million in planned insider sales from two affiliated venture funds
Risk Factors
- Potential downward pressure on stock price if sales are executed rapidly
- Signal of waning confidence from early institutional investors
- Increased share supply in a potentially illiquid biotech stock
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (DYN), Batch item 1 | 0001628280-26-026024 |
| Document: 0001628280-26-026024-index.html | 0001628280-26-026023 |
| Document: 0001628280-26-026024.txt | 0001628280-26-026024 |
| 144 Filing (DYN), Batch item 4 | 0001628280-26-026023 |
| Document: 0001628280-26-026023-index.html | 0001628280-26-026024 |
| Document: 0001628280-26-026023.txt | 0001628280-26-026024 |
Track record
54 reports on DYN
11 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers